Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
The Brain as a Target of Inflammatory Processes
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Mechanism of action of mitoxantrone.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Biogen Idec's TECFIDERA™ (dimethyl fumarate) approved in US as a first-line oral treatment for multiple sclerosis
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Glial Biology: Functional Interactions Among Glia & Neurons (Gordon Research Seminar)
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Episode 19 with Dr. Samuel Ludwin on treating MS subtypes
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.
Episode 13 with Professor Alan Thompson on the International Progressive MS Alliance.
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.
The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample.
GlaxoSmithKline Product Development Pipeline

Pages